Oxygen Biotherapeutics Inc.

EANS-Adhoc: Oxygen Biotherapeutics Reports Second Quarter FY2011 Financial Results

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide   distribution. The issuer is solely responsible for the content of this   announcement. --------------------------------------------------------------------------------@@end@@

quarterly report


DURHAM, NC, December 9, 2010 — Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) second quarter ended October 31, 2010.

Highlights (activity through December 9, 2010) •Received $245,000 grant under the Patient Protection and Affordable Care Program Act •Secured listing on leading on-line beauty retail websites for DERMACYTE skin care products: Dermstore.com and Beautyriche.com •Granted DSMB Approval to proceed to second cohort of STOP-TBI Phase II-b trials •In November, the Company issued a promissory note under Note Purchase Agreement with Vatea Fund in the amount of $600,000

"While still moderate at this stage, DERMACYTE sales continued to rise slowly, yet steadily, during the quarter. In October we hired a top-notch sales director whose 15 years of experience in dermatological and skin care sales will elevate our sales effort to the next level," said Chris Stern, Chairman & Chief Executive Officer of Oxygen Biotherapeutics. "Our efforts next quarter will focus on DERMACYTE sales and R&D, while managing expenses."

Second Quarter Results Oxygen Biotherapeutics reported net revenue of $27,126 for the second quarter of fiscal 2011, compared to $6,561 for the comparable quarter the previous year due to increased sales of DERMACYTE products.

Total operating expenses for the period ended October 31, 2010 were $2,083,863 compared to $2,593,051 for the same period in 2009. These expenses were driven primarily by an increase in R&D payroll and clinical trial costs, offset by a decrease in SG&A expenses due to a decrease in legal, accounting and consulting fees, as well as lower other income and interest expenses.

For the second quarter period ended October 31, 2010, the Company reported a net loss of approximately $2.0 million, or $0.09 per share, compared to a net loss of approximately $2.6 million, or $0.13 per share for the same period in the prior year. The decrease in net loss for the quarter was primarily due to a decrease in legal, accounting and consulting fees, compensation, and lower development and manufacturing costs for Oxycyte. The net loss was partially offset by an increase in sales and marketing expenses related to the marketing and sales efforts for DERMACYTE products and an increase in research and development costs that can be attributed to our traumatic brain injury Phase II-b trials and payroll.

Six Month Results Net revenue for the six months ended October 31, 2010 was $32,236 compared to total revenue of $6,561 for the same period in fiscal year 2010. This was primarily due to DERMACYTE product sales.

For the six-month period ending October 31, 2010 the company had total operating expenses of $5,112,174 compared to $4,883,586 for the same period in 2009.  The increase is primarily due to costs incurred for compensation, clinical trials, development and manufacture of Oxycyte, a reduction in costs incurred for stock-based compensation, and marketing and sales expenses for DERMACYTE products.

The Company reported a net loss of $5,054,236, or $0.22 per share for the six month period ended October 31, 2010, compared to a net loss of $4,985,890, or $0.28 per share for the same period in 2009.

As of October 31, 2010, the Company had cash and cash equivalents totaling $837,167, up from $632,706 at April 30, 2010.

Conference Call Management will host a conference call on Friday, December 10, 2010 at 11 a.m. EST. To access the live teleconference dial (866) 825-3209 (U.S. and Canada) or (617) 213-8061 (international.)  The participant passcode is 81091554. A live webcast will be available on our web site http://www.oxybiomed.com/investors.htm. A replay of the webcast will be available on the Oxygen Biotherapeutics website, or by phone for a limited time. To access the replay by phone, call (888) 286-8010 (U.S. and Canada) or (617) 801-6888 (international) for a limited time. The passcode for the replay is 25705024.

Caution Regarding Forward-Looking Statements This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include the expansion of development of the Oxycyte and DERMACYTE product lines and the timing of the introduction of those new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current reports on Form 10-Q and Form-10K. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

end of ad-hoc-announcement ========================================== ====================================== About Oxygen Biotherapeutics, Inc.

Headquartered in Durham, NC, Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte that is being formulated for both intravenous and topical delivery. Potential indications include traumatic brain injury, decompression sickness, wounds and pruritis. This year, the company launched its DERMACYTE® line of oxygen-rich skin care products. More information is available at www.oxybiomed.com or www.buydermacyte.com.

@@start.t2@@end of announcement                                                 euro adhoc

Further inquiry note: Ellen Corliss Vice President, Corporate Communications & Investor Relations Oxygen Biotherapeutics, Inc 2530 Meridian Pkwy, 3rd floor Durham, NC 27713 Direct Telephone: +1 919 855 2112 Direct Fax: +1 919 806 4417 Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN:      US69207P2092
WKN:        10728277
Index:    SSIRT
Börsen:  New York / Nasdaq
              SIX Swiss Exchange / Main Standard

Weitere Meldungen: Oxygen Biotherapeutics Inc.

Das könnte Sie auch interessieren: